Research programme: schizophrenia and depression therapeutics - Affectis PharmaceuticalsAlternative Names: AF-4025
Latest Information Update: 16 Jul 2016
At a glance
- Originator Affectis Pharmaceuticals
- Mechanism of Action Purinergic P2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Major depressive disorder; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Major depressive disorder in Germany